A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma

Table 2 Toxicities of the h-R3/RT and CDDP/RT groups (N = 104)

Toxicities (RTOG Grade)	h-R3/RT (N = 52) [n (%)]	CDDP/RT (N = 52) [n (%)]	P Value*
WBC			0.048*
(1&2)	32 (61.5%)	32 (61.5%)
(3&4)	1 (1.9%)	7 (13.5%)
PLT			0.752
(1&2)	19 (36.5%)	18 (34.6%)
(3&4)	1 (1.9%)	2 (3.8%)
HB			0.499
(1&2)	27 (51.9%)	26 (50%)
(3&4)	0 (0.00%)	0 (0.00%)
ALT			0.294
(1&2)	10 (19.1%)	8 (11.9%)
(3&4)	0 (0.00%)	0 (0.00%)
AST			0.197
(1&2)	10 (19.2%)	5 (9.6%)
(3&4)	0 (0.00%)	0 (0.00%)
GGT			0.166
(1&2)	9 (17.3%)	5 (9.6%)
(3&4)	0 (0.00%)	0 (0.00%)
Dermatitis			0.445
(1&2)	33 (63.5%)	44 (84.6%)
(3&4)	2 (3.8%)	1 (1.9%)
Rash			0.248
(1&2)	5 (9.6%)	3 (5.8%)
(3&4)	1 (1.9%)	0 (0.00%)
Mucositis			0.093
(1&2)	21 (40.4%)	26 (50%)
(3&4)	30 (57.7%)	25 (48.1%)
Taste change			0.763
yes	46 (88.5%)	47 (90.4%)
no	6 (11.5%)	5 (9.6%)
Vomit			0.000*
only nausea	12 (23.1%)	2 (3.8%)
nausea and vomit	5 (9.6%)	43 (78.8%)
Weight loss			0.249
(1&2)	26 (50.0%)	30 (57.7%)
(3&4)	13 (25.0%)	15 (28.8%)

Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/RT cisplatin and radiotherapy. WBC white blood cell, PLT Platelets, HB hemoglobin, ALT alanine transaminase, AST glutamic-oxalacetic transaminease, GGT gamma glutamyl transpeptidase
*All p values were obtained by the paired rank sum test

ISSN: 1471-2407